- Home
- FERA vs CERS Comparison
FERA vs CERS Comparison
Compare FERA & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FERA
- CERS
- Stock Information
- Founded
- FERA 2024
- CERS 1991
- Country
- FERA Cayman Islands
- CERS United States
- Employees
- FERA N/A
- CERS N/A
- Industry
- FERA
- CERS EDP Services
- Sector
- FERA
- CERS Technology
- Exchange
- FERA Nasdaq
- CERS Nasdaq
- Market Cap
- FERA 317.4M
- CERS 265.7M
- IPO Year
- FERA 2025
- CERS 1997
- Fundamental
- Price
- FERA $10.17
- CERS $1.33
- Analyst Decision
- FERA
- CERS Strong Buy
- Analyst Count
- FERA 0
- CERS 2
- Target Price
- FERA N/A
- CERS $3.50
- AVG Volume (30 Days)
- FERA 1.5K
- CERS 880.5K
- Earning Date
- FERA 01-01-0001
- CERS 08-05-2025
- Dividend Yield
- FERA N/A
- CERS N/A
- EPS Growth
- FERA N/A
- CERS N/A
- EPS
- FERA N/A
- CERS N/A
- Revenue
- FERA N/A
- CERS $185,144,000.00
- Revenue This Year
- FERA N/A
- CERS $20.97
- Revenue Next Year
- FERA N/A
- CERS $15.55
- P/E Ratio
- FERA N/A
- CERS N/A
- Revenue Growth
- FERA N/A
- CERS 13.06
- 52 Week Low
- FERA $10.00
- CERS $1.12
- 52 Week High
- FERA $10.60
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- FERA N/A
- CERS 43.86
- Support Level
- FERA N/A
- CERS $1.34
- Resistance Level
- FERA N/A
- CERS $1.41
- Average True Range (ATR)
- FERA 0.00
- CERS 0.07
- MACD
- FERA 0.00
- CERS -0.01
- Stochastic Oscillator
- FERA 0.00
- CERS 4.17
About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares
Fifth Era Acquisition Corp I is a blank check company.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.